Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
Date:12/12/2011

94

 

$   42,141,198 

 

 

 AVANIR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 

 

 

 

 

 

 

  Three Months Ended September 30, Twelve Months Ended September 30, 2011 2010 2011 2010REVENUES FROM PRODUCT SALES 

 

 

 

 

 

 Gross product sales

$
4,322,688

 

$
-

 

$
7,014,778

 

$
-Less: discount and allowances

627,631

 

-

 

925,472

 

-Net product sales

3,695,057

 

-

 

6,089,306

 

-Cost of product sales

212,445

 

117,640

 

445,980

 

197,640Product gross margin (loss)

3,482,612

 

(117,640)

 

5,643,326

 

(197,640) 

 

 

 

 

 

 

 OTHER REVENUES 

 

 

 

 

 

 Revenues from royalties

1,065,713

 

(71,304)

 

4,406,589

 

2,895,474Total gross margin

4,548,325

 

(188,944)

 

10,049,915

 

2,697,834 

 

 

 

 

 

 

 OPERATING EXPENSES 

 

 

 '/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
2. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
3. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
4. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
6. Avanir Pharmaceuticals to Participate in Two Investor Conferences
7. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
8. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
9. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
10. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
11. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... Calif. , June 29, 2015 /PRNewswire/ ... of advanced visual prosthetic devices for the ... announced the publication of "Long-Term (60-month) Results ... Safety Outcomes Stratified by Age in Patients ... Clinical Ophthalmology . The 5-year data show ...
(Date:6/29/2015)... 29, 2015 /PRNewswire/-- CytRx Corporation (NASDAQ: CYTR ), ... today announced the presentation of interim results from its ... and safety of aldoxorubicin for the treatment of Kaposi,s ... presented on Wednesday, July 1, 2015 during a poster ... Herpesvirus (KSHV) and Related Agents in Hollywood, ...
(Date:6/29/2015)... , June 29, 2015  The automotive ... features to cars on the basis of consumer ... industry is now on the verge of integrating ... While automotive HWW non-critical features such as reconfigurable ... present in 30 to 40 percent of all ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 2CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 3CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 4CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 6Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Ouchless ® Needle by BellaNovus Development Company ... Dr. Mariano Busso is the latest in a growing ... its use for cosmetic injections. Dr. Busso is on ... localized pain resulting from cosmetic injections. Ouchless ® ...
... a critical care company focused on developing and commercializing ... the U.S. Food and Drug Administration (FDA) has granted ... oxide (iNO) with the INOpulse® DS drug-delivery system as ... investigational new drug application (IND) for PAH was submitted ...
Cached Medicine Technology:New Ouchless® Needle Collection Announces Leading Dermatology Testimonial 2FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 2FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 3FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 4
(Date:6/29/2015)... Van Nuys, CA (PRWEB) , ... June 29, ... ... release of its new YouTube video, “Lake Balboa Care Center”, showcasing its prestigious ... health inspections, staffing, and quality measures. Lake Balboa views this rating as indicative ...
(Date:6/29/2015)... ... June 29, 2015 , ... A state-of-the-art implant ... Cornell Medical Center. The device is the first of its kind approved by ... airway pressure (CPAP), the current standard of care for OSA. , Some 18 ...
(Date:6/29/2015)... ... June 29, 2015 , ... World ... Fresh Plus Diaper, a baby invention that makes parenthood less tiring without sacrificing ... reach a market value of USD 52.2 billion in 2017," says Scott Cooper, ...
(Date:6/29/2015)... ... June 29, 2015 , ... National ... auditor of customer service for the 40-center nursing home group. Sixteen of their ... centers in the United States in one or more customer service areas. Those ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... developed a new approach to build nearly complete genomes by combining high-throughput DNA ... genomic variation, critically important for their association with human disease, but previously difficult ...
Breaking Medicine News(10 mins):Health News:Lake Balboa Releases New Facility Video of Patient Testimonials 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4
... studies demonstrated potential for pazopanib as a single,agent treatment for early stage ... In patients with stage I-III non-small cell lung cancer, 86 percent of ... reduction in tumor volume -- ... response rate of 35 percent. The median duration ...
... medication use in young children has been linked to ... leading the FDA to recommend against their use for ... about safety and efficacy, there has been little research ... very young children. Now, a new study from the ...
... offer help to millions of diabetics who are missed ... and diagnosis for diabetes is being called for to ... have the disease, a new report says. , "Approximately ... States are undiagnosed," study author Dr. Christopher Saudek, of ...
... on,Mental Illness (NAMI) will honor television journalist Jane ... illness at NAMI,s annual,convention in Orlando, Florida, June ... made the announcement today in,the NAMI Blog ... of,two television documentaries that NAMI was closely involved ...
... The American Lung,Association of Iowa will host a week long ... The camp is open for all children with,asthma from ages 7 ... kids with asthma to spend a week doing,things all other kids ... Association, "It is a chance for kids to learn that,having asthma ...
... tiny, specific pieces of non-coding genetic material known as ... of cancer to other parts of the body. Researchers ... and Ohio State University Medical Center in Columbus have ... miRNAs. The findings, reported at the annual meeting of ...
Cached Medicine News:Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:Study examines cold medication use in young children 2Health News:Panel Calls for Better Diabetes Screening 2Health News:NAMI Blog: PBS, MTV and Jane Pauley 2Health News:Jefferson, Ohio State team find gene signature profile for metastasis 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: